Results 31 to 40 of about 112,750 (306)
Purification, Characterization and Biological Activity of Polysaccharides from Dendrobium officinale
Molecules, 2016 Polysaccharide (DOPA) from the stem of D. officinale, as well as two fractions (DOPA-1 and DOPA-2) of it, were isolated and purified by DEAE cellulose-52 and Sephacryl S-300 chromatography, and their structural characteristics and bioactivities were ...
Kaiwei Huang +6 more
doaj +1 more source
Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39. [PDF]
PLoS ONE, 2014 OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death under oxidative stress. METHODS: PC12 cells were treated with L-DOPA at different concentrations. We detected the L-DOPA induced reactive oxygen
Shi-Ying Zhong +5 more
doaj +1 more source
Biosensors, 2022 Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson’s disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects
Lu Fang +9 more
doaj +1 more source
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. [PDF]
, 2017 ObjectiveParkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on quality of life and association with poorer outcomes.
Bizzarri +29 more
core +2 more sources
European Thyroid JournalObjective: Correct diagnosis and prognostic evaluation of medullary thyroid cancer (MTC) are crucial to treat patients. The purpose of this study was to evaluate the diagnostic and prognostic value of [18F]F-DOPA PET/CT in patients with MTC.
Zhaoqi Zhang +9 more
doaj +1 more source
Frontiers in Aging Neuroscience, 2021 BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima +8 more
doaj +1 more source
Journal of Parkinson’s Disease, 2017 Today we would find it difficult to place ourselves in the position of the physician or the patient prior to the L-DOPA era of Parkinson’s Disease (PD). David Marsden, the eminent British neurologist, neuroscientist and PD researcher of the second half of the last century and an eyewitness to that historical turning point, paints with few brush strokes,
openaire +3 more sources
Mortality in Parkinson's disease : A systematic review and meta-analysis [PDF]
, 2014 © 2014 International Parkinson and Movement Disorder Society.Peer reviewedPublisher ...
Greenland S +3 more
core +1 more source
Neurobiology of Disease, 2011 The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles +3 more
doaj +1 more source
The Scientific World Journal, 2014 We incorporated anti-Parkinsonian drug, levodopa (dopa), in Zn/Al-LDH by coprecipitation method to form dopa-LDH nanocomposite. Further coating of Tween-80 on the external surfaces of dopa-LDH nanocomposite was achieved through the oxygen of C=O group of
Aminu Umar Kura +3 more
doaj +1 more source